Literature DB >> 11793434

Effects of storage and viral load on hepatitis C viral genotyping.

D A Payne1, S L Seifert, B A Brody.   

Abstract

Hepatitis C virus (HCV) genotyping is important for determining the treatment protocol for hepatitis C patients. Since amplified material from the Roche HCV Monitor kit is compatible with the Innogenetics INNO-LiPA HCV II kit (line probe assay), amplicons from the Monitor assay can be used to identify the HCV genotype. The Monitor package insert recommends using amplicons within a 7-day period (at 4 degrees C) following amplification. It was hypothesized that storage of amplicons for 4 weeks and longer (at -20 degrees C) would not affect the sensitivity of the genotyping assay. After denaturation, amplicons from two genotypes were stored for 7-386 days prior to performing the genotyping assay. Storage of amplicons did not hamper the ability to identify the genotype. Additionally, the sensitivity of the assay was evaluated by analyzing five genotypes with low viral loads. HCV genotypes were detected most consistently at viral levels of 10,000 copies/mL. In conclusion, the Innogenetics genotyping assay can use stored amplicons, thus reducing the cost of the assay by avoiding additional PCR reactions. Determining the sensitivity of this assay facilitates the efficient use of this test by incorporating a sensitivity cutoff of >or=10,000 copies/mL. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11793434      PMCID: PMC6808175          DOI: 10.1002/jcla.1046

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

1.  Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy.

Authors:  P Pradat; P Chossegros; F Bailly; P Pontisso; G Saracco; S Sauleda; M Thursz; H Tillmann; H Vlassopoulou; A Alberti; J H Braconier; J I Esteban; S Hadziyannis; M Manns; M Rizzetto; H C Thomas; C Trépo
Journal:  J Viral Hepat       Date:  2000-05       Impact factor: 3.728

2.  Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

Authors:  Z M Younossi; M E Singer; J G McHutchison; K M Shermock
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

3.  Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection.

Authors:  A Berger; M von Depka Prondzinski; H W Doerr; H Rabenau; B Weber
Journal:  J Med Virol       Date:  1996-04       Impact factor: 2.327

Review 4.  Prediction of response to interferon treatment of chronic hepatitis C.

Authors:  G L Davis
Journal:  J Hepatol       Date:  1994-07       Impact factor: 25.083

5.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

6.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

7.  At least five related, but distinct, hepatitis C viral genotypes exist.

Authors:  T A Cha; E Beall; B Irvine; J Kolberg; D Chien; G Kuo; M S Urdea
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

8.  Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.

Authors:  J B Nousbaum; S Pol; B Nalpas; P Landais; P Berthelot; C Bréchot
Journal:  Ann Intern Med       Date:  1995-02-01       Impact factor: 25.391

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants.

Authors:  S W Chan; F McOmish; E C Holmes; B Dow; J F Peutherer; E Follett; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.